Biotech

Themenbereich / / Biotech


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Microbix Completes Brokered Private Placement

TORONTO, ONTARIO -- (Marketwired) -- 10/19/17 -- Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units ("Units") at a price of $0.30 per unit.Each Unit consists of one common share ("Common Share") of Microbix and one-half of one warrant to purchase one Common Share. Each whole warrant ("Warrant") entitles the hold ...

19.10.2017

Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement

LONDON, ONTARIO and BOSTON, MASSACHUSETTS -- (Marketwired) -- 10/18/17 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the closing of the second tranche of a $2 million non-brokered private placement announced September 20, 2017. In the second tranche, the Company issued 482,686 units (the "Units") at a price of CAD $1.16 per Unit, for additional gross proceeds of approximately CAD $5 ...

18.10.2017

Orgenesis to Present at BIO Investor Forum

GERMANTOWN, MD -- (Marketwired) -- 10/18/17 -- Orgenesis Inc., (OTCQB: ORGS) ("Orgenesis " or "the Company"), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today announced that it will present at the BIO Investor Forum being held October 17-18, 2017 in San Francisco, CA.Vered Caplan, Chief Executive Officer of Orgenesis, will be giving a live presentation and meeting with investors throughout the conference.BIO Investor Forum Wednesday, October 18, 2017 9:30am PT (Pacific Time) The Wes ...

18.10.2017

Seventh Peer Reviewed Publication on Angle''s Parsortix(TM) System

GUILDFORD, SURREY -- (Marketwired) -- 10/17/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)AIM:AGL OTCQX:ANPCYParsortix™ system outperforms other approaches to harvest circulating tumour cells from the blood of clear cell renal cell carcinoma patientsThe Parsortix™ system demonstrated the highest recovery rate and the highest purity of all evaluated systemsANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix™ system is the subject of a peer-reviewed publication in the journal Oncotarget detailing work undertaken by ANGLE''s customer, U ...

17.10.2017

Trillium Therapeutics'' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

TORONTO, ONTARIO -- (Marketwired) -- 10/16/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.Oral Presentation O-16: CD47 Blockade with TTI-621 (SIRPalphaFc) in Sezary SyndromePresenter: Dr. Oleg Akilov, University of Pit ...

16.10.2017

Realm Therapeutics Announces Completion of $26 million Private Placement

MALVERN, PA -- (Marketwired) -- 10/12/17 -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces that the private placement of $26 million (the "PIPE") that it previously disclosed on September 21, 2017, was approved by its shareholders at a general meeting held in London on October 9, 2017 and has been completed today. The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to trading on AIM, a market operated by the London Stock Exchange, on October 10, ...

12.10.2017

ANGLE plc Announces Proposed Further Subscription for £ 2.8 Million

GUILDFORD, SURREY -- (Marketwired) -- 10/12/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)AIM:AGL OTCQX:ANPCYANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that further to the announcement on 5 October 2017, the Company has conditionally raised approximately £ 2.8 million by way of a subscription for 7,481,570 new Ordinary Shares (the "Further Subscription Shares") at a price of 37.5 pence each (the "Further Subscription"). The Further Subscription is in addition to the Fundraising to raise approximately £ 12.2 million (before exp ...

12.10.2017

VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona

CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 10/11/17 -- VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI''s enveloped virus-like particle (eVLP) platform, highlighting data from two of the company''s vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barcelona.During the presentation, Mr. Buckley will provide a synopsis of VBI''s eVLP technology, including an overview of the positive interim data from the Phase I clinic ...

11.10.2017

Microbix Announces End of Legal Dispute

TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, is pleased to announce the withdrawal of legal claims alleging patent infringement that were filed in Canadian Federal Court against Microbix by ZeptoMetrix Corporation in October, 2016.The allegations by ZeptoMetrix have been withdrawn, following a settlement reached by the two companies. The withdrawal of the lawsuit is "with prejudice," meaning that these allegations cannot be reasserted in Federal Court by ZeptoMetrix in the future."Th ...

11.10.2017

Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma

LONDON, ONTARIO and BOSTON, MASSACHUSETTS -- (Marketwired) -- 10/11/17 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that the first patient was dosed in the head and neck squamous cell carcinoma (HNSCC) arm of its Phase 1 trial of COTI-2 at a dosage level of 1.0 mg/kg."There is a clear need to develop new medicines for HNSCC, which affects nearly 450,000 patients in the U.S., many of who ...

11.10.2017

Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors

TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that Dr. Helen Tayton-Martin has been appointed to its board of directors.Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Ada ...

11.10.2017

Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology

TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced positive initial results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-i ...

11.10.2017

Arch Biopartners Initiates Manufacturing Process for Metablok

TORONTO, ONTARIO -- (Marketwired) -- 10/10/17 -- Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) a portfolio-based biotechnology company, today announced it has engaged CSBio in Menlo Park, California, to begin the manufacturing process for Metablok, the Company''s drug candidate for treating inflammation, cancer metastasis and sepsis.Arch is planning a Phase I human trial to evaluate Metablok''s safety and pharmacokinetic profile. The phase I study will be followed by Phase II clinical trials to evaluate the efficacy of Metablok in prevent ...

10.10.2017

ANGLE plc Announces Circulating Tumour Cells, Harvested From Blood, Grown in the Laboratory for the First Time

GUILDFORD, SURREY -- (Marketwired) -- 10/09/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY),AIM: AGL; OTCQX: ANPCYHeinrich Heine University researchers demonstrate that CTCs harvested with Parsortix™ from leukapheresis blood product can be culturedCultured cells continue to proliferate several months after Parsortix™ harvestANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that one of its customers has successfully grown circulating tumor cells (CTCs) harvested by Parsortix™ in the laboratory. This is the first time the ability to culture CTCs harvested from ...

09.10.2017

ANGLE plc Announces Parsortix(TM) System Central to Potential New Analytical Protocol for Identifying Drugs That May Arrest Metastasis

GUILDFORD, SURREY -- (Marketwired) -- 10/09/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)AIM: AGL; OTCQX: ANPCYReal time technique being developed to assess the impact of cancer drugs on living circulating tumour cells harvested from patient blood using Parsortix™ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that Professor Stuart Martin from the University of Maryland School of Medicine, USA, presented new breakthrough research using ANGLE''s Parsortix™ system at Europe''s leading circulating tumour cell (CTC) conference, the Third ...

09.10.2017

Angle''s Parsortix(TM) System Showcased in Multiple Presentations at Leading European Circulating Tumour Cell Conference

GUILDFORD, UNITED KINGDOM -- (Marketwired) -- 10/09/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)AIM: AGL; OTCQX: ANPCYTraction of Company''s CTC harvesting system accelerating as customers and key opinion leaders feature Parsortix™ in 8 posters and five plenary presentationsWell positioned to become default cancer liquid biopsy systemANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix™ system was widely showcased by the Company''s customers and Key Opinion Leaders in the field of circulating tumour cells (CTCs) in pres ...

09.10.2017

Angle PLC: Results of Fundraising

GUILDFORD, SURREY -- (Marketwired) -- 10/05/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)(AIM:AGL OTCQX:ANPCY)ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading player in the liquid biopsy market, is pleased to announce that, further to the announcement made earlier today, the Company has successfully raised a total of approximately £ 12.2 million (before expenses) with new and existing investors consisting of 3,757,146 EIS/VCT Placing Shares, 25,680,006 General Placing Shares, 772,857 General Subscription Shares and 4,579,169 Covington Subscription Shares, all at a price of 35 pence per New Ordinary Sha ...

05.10.2017

Theratechnologies Announces Financial Results for Third Quarter of 2017

MONTREAL, QUEBEC -- (Marketwired) -- 10/05/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2017.Third quarter 2017 financial highlights"With three quarters into our fiscal year, our business plan is very much on track. Sales of EGRIFTA® are growing and the ibalizumab file is progressing as we anticipated. In fact, we are even ahead of our plan for ibalizumab in Europe as we started investing in regulatory work much sooner than we expected," said Luc Tanguay, President and Chief Executive Officer ...

05.10.2017

Angle PLC: Angle PLC Announces Proposed Placing of 29,437,152 New Ordinary Shares at 35 pence per share Proposed subscriptions of 5,352,026 New Ordinary Shares at 35 pence per share Conditional Acquisition of certain assets of Axela Inc.

GUILDFORD, SURREY -- (Marketwired) -- 10/05/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)(AIM: AGL; OTCQX: ANPCY)ANGLE plc (AIM: AGL; OTCQX: ANPCY), a leading player in the liquid biopsy market, today announces the conditional acquisition of certain assets of Axela Inc. ("") for a total consideration payable, subject to certain balancing adjustments, of CAD6.15 million (approximately £ 3.7 million) (the ""), together with a conditional Placing and subscriptions (including a subscription by Covington, Axela''s major shareholder and creditor) to raise in aggregate appr ...

05.10.2017

Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017(TM)

MONTREAL, QUEBEC -- (Marketwired) -- 10/04/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced 48-week efficacy and safety results for ibalizumab in patients infected with multidrug resistant HIV-1 who completed the 24-week Phase III study (TMB-301) and continued treatment in the Expanded Access Program study (TMB-311). These data are being presented in an oral presentation at IDWeek 2017™ in San Diego (abstract #1686).Of the 27 patients who completed the 24-week treatment period of TMB-301 in the U.S., all entered TMB-311, where patients continued to receive ibalizuma ...

04.10.2017


Page 1 from 245:  1 2  3  4  5  .. » 245





All members: 8 010
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.